Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Hanschitz, HD.
Überlebenszeit und Überlebensqualität bei palliativer Therapie des Ösophaguskarzinoms
[ Diplomarbeit/Master Thesis ] Graz Medical University; 2010. pp.55.
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Lindenmann Jörg
- Smolle-Juettner Freyja-Maria
- Altmetrics:
- Abstract:
- Background: Esophageal carcinoma is often diagnosed in an advanced tumour stage. In such cases only palliative therapy options can be considered. Carcinoma of the oesophagus is predominantly found in male patients aged between 60 and 80 years. The aim of the study was, to analyze the efficiency of the various therapeutic measures and to asses the influence of gender on various tumor- and/or treatment related parameters. Methods: We did a retrospective analysis based on the data of patients with esophageal carcinoma treated under palliative intention at the Division of Thoracic and Hyperbaric Surgery between 1999 and 2009. The informations were derived from the hospital information System Medocs and from the patientsdata sheets. A total of 250 patients were included into the study. Results: Our study confirmed the epidemiological prevalence of the male gender in esophageal carcinoma (85% vs. 15%). Alcohol consumption was a significant risk factor. There was no gender-specific statistically significant difference in features of the patients history, symptoms, clinical findings at the time of admission, tumour type or stage and outcome. In the majority of patients more than one palliative treatment modality was applied, combining endoluminal interventional procedures with chemo- or radiotherapy. The median survival time after multimodal palliative treatment of esophageal carcinoma was 34 months. For men it was 32.8 months, which is on average 7.2 months longer than for female patients 25.6 months. The difference is not statistically significant, however. Considering the impact of the initial treatment modality on survival, photodynamic therapy showed the best results: The median survival rate amounted to 50.9 months at a 5 years survival rate of 55 %, whereas in the multimodal setting without initial PDT the median survival was 17.3 months (p= 0,012). Conclusion: By using a combination of different modalities, the palliative therapy of esophageal carcinoma yields long survival times. Considering the efficacy of the intital treatment modality, photodynamic therapy was the most effective one. The female collective of patients was much smaller than the male one. In contrast to many other malignancies, there was not any gender-specific statistically significant difference concerning patients history, symptoms, clinical features, tumour type or stage and outcome.